Oragenics, Inc. is focused on becoming a leader in novel antibiotics against infectious disease. The company is currently developing innovative treatments for oral mucositis and infectious disease. Its Phase 2, FDA fast tracked, orphan status oral mucositis program features a live biotherapeutic to deliver trefoil factor to injured tissue, while its antibiotic platform features lantibiotics, which are novel peptide anti-bacterial compounds produced by gram positive bacteria strains that attack disease mitigating bacteria. Oragenics has established two exclusive worldwide channel collaborations with Intrexon Corporation subsidiaries, which will allow Oragenics to accelerate the development of both programs.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):